Foghorn Therapeutics, a preclinical biotech developing gene therapies for hematologic cancers and solid tumors, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Foghorn is developing a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system through its proprietary Gene Traffic Control platform. The company's two most advanced candidates are FHD-286, a selective allosteric ATPase inhibitor, and FHD-609, a protein degrader. The candidates are being developed for hematologic cancers and solid tumors, and the company plans to file INDs for FHD-286 and FHD-609 in the 4Q20 and 1H21, respectively.
The Cambridge, MA-based company was founded in 2015 and plans to list on the Nasdaq under the symbol FHTX. Goldman Sachs, Morgan Stanley, Cowen and Wedbush PacGrow are joint bookrunners on the deal. No pricing terms were disclosed.
Friday, October 2, 2020
Preclinical oncology biotech Foghorn Therapeutics files for $100M IPO
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.